Dr. Korkos' Expertise to Help Build New Opportunities
LAS VEGAS, Oct. 26 /PRNewswire-FirstCall/ -- As part of its strategy to continue to expand its product pipeline and pharmaceutical contacts, Skinvisible, Inc. (OTC Bulletin Board: SKVI) http://www.skinvisible.com, the developers of Invisicare(R), a patented polymer delivery system for topical skincare products, today announced the appointment of George J. Korkos, M.D. to its Advisory Board. Dr. Korkos is a nationally renowned plastic and reconstructive surgeon and is also known for his business acumen.
"We are pleased to have such a distinguished world-class plastic surgeon agree to contribute his medical and business expertise to Skinvisible as we continue to develop our polymer delivery technologies and new topical products for the global marketplace," said Mr. Terry Howlett, President / CEO of Skinvisible. "Dr. Korkos will be a great addition to our Board. He has the medical expertise, business experience, contacts and enthusiasm to assist us in bringing Skinvisible and our products in front of new companies, both in the medical/plastic surgery area and the investment community. He has ideas for new applications for our technology and will assist us in taking these products from concept to commercialization."
"I am pleased to be asked to serve on the Advisory Board of Skinvisible, Inc." said Dr. Korkos. "They have an exciting technology that I believe has many interesting applications in the medical field. The skincare industry is looking for new innovation to enhance their product lines and the Invisicare delivery technology does exactly that. I also like the fact that Skinvisible is dedicated to R&D and protecting their intellectual property at every turn; that's key in this industry."
Dr. Korkos received his degree from the Medical College of Wisconsin and did his plastic surgery residency at St. Louis University. He is currently the President of Plastic Surgery Associates in Milwaukee, Wisconsin and Blue Mound Surgery Center along with being an Associate Clinical Professor at the Medical College of Wisconsin. Recently Dr. Korkos was honored with the establishment of the first endowed chair at the Medical College of Wisconsin; The George J. Korkos Chair in Plastic Surgery. His business background is diverse. Along with sitting on Boards of emerging companies, Dr. Korkos has also served on the Board of a number of financial and investment institutions.
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals, a wholly owned subsidiary of Skinvisible Inc., is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the patent. http://www.skinvisible.com
Invisicare is a patented polymer delivery system developed to hold active ingredients topically on the skin for extended periods of time. A key benefit is that Invisicare is non-occlusive on the skin, allowing normal skin respiration and perspiration. The Company has developed a portfolio of topical products using Invisicare for the dermatology and cosmeceutical industries. http://www.invisicare.com
This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007)
|SOURCE Skinvisible, Inc.|
Copyright©2007 PR Newswire.
All rights reserved